Company: HCTI
Filing Date: 2025-05-15
Form Type: 424B4
Source: 0001213900-25-044095
Chunk: 15

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-15
Form: 424B4
Chunk 15
---
)(3)(A)(iii), if the closing price of our Common Stock is $0.10 or less
for 10 consecutive trading days, we will be issued a Nasdaq delisting determination notice. The likelihood of our Common Stock trading
below $0.10 for 10 consecutive trading days is significantly increased by registration of Purchase Warrants under the registration statement
related to this prospectus as up to 361,904,850 shares of our Common Stock could be issued at an exercise price as low as $0.084 per
share pursuant to the Series A Warrants and up to 1,085,714,550 shares of our Common Stock could be issued at an exercise price of zero
pursuant to the Series B Warrants. If we receive a Nasdaq delisting determination notice resulting from our Common Stock trading at or
below $0.10 for 10 consecutive trading days, we will have seven calendar days to request a hearing before a Nasdaq hearings panel to
review such delisting determination, which will stay the delisting of our Common Stock by Nasdaq. A hearing would then take place within
45 days of the hearing request to determine whether or not our Common Stock would be delisted. If, in the future, we receive a Nasdaq
delisting determination notice there can be no assurance that we would be successful in preventing a determination by the Nasdaq hearing
panel that our stock will be delisted.

<div align='center'>6</div>

The issuance and exercise of the Series B Warrants could be a significant factor in Nasdaq using its discretionary authority to make a delisting determination or suspending trading of our Common Stock.

Under Listing Rule 5101, Nasdaq has broad
discretionary authority to suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs
that makes continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities
meet all enumerated criteria for continued listing on Nasdaq. We are aware of public disclosure made by another Nasdaq listed company
that is listed on the Nasdaq Global Market (the “Other Listed Company”) that discloses on April 25, 2025, the Other Listed
Company received a notification letter from Nasdaq (the First April Notice”), stating that based on its review of the Othe Listed Company’s public filings with the SEC, Nasdaq determined to delist the Other Listed Company’s securities pursuant to